Clinical aspects of inflammation in Alzheimer's disease (Q36364213)

13 August 2017

1 reference

title

Clinical aspects of inflammation in Alzheimer's disease (English)

1 reference

13 August 2017

0 references

0 references

Paul B Rosenberg

1

1 reference

13 August 2017

publication date

1 December 2005

1 reference

International Review of Psychiatry

13 August 2017

published in

1 reference

13 August 2017

volume

17

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

503-514

1 reference

A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Beta-amyloid-induced glial expression of both pro- and anti-inflammatory cytokines in cerebral cortex of aged transgenic Tg2576 mice with Alzheimer plaque pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Predicting nursing home admission: estimates from a 7-year follow-up of a nationally representative sample of older Americans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Visualising microglial activation in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Neuropathological imaging: in vivo detection of glial activation as a measure of disease and adaptive change in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Reduced long-term potentiation in the dentate gyrus of transgenic mice with cerebral overexpression of interleukin-6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Reduced beta-amyloid production and increased inflammatory responses in presenilin conditional knock-out mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Immunological aspects of microglia: relevance to Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Predictors of nursing facility admission: a 12-year epidemiological study in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Executive dysfunction in early Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Galantamine provides sustained benefits in patients with 'advanced moderate' Alzheimer's disease for at least 12 months

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Patterns of brain activation in people at risk for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

APOE-epsilon4 count predicts age when prevalence of AD increases, then declines: the Cache County Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

NSAIDs and Alzheimer's disease: how far to generalise from trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Relevance of functional neuroimaging in the progression of mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

In-vivo measurement of activated microglia in dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Cytokines and psychopathology: lessons from interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

The temporal relationship between depressive symptoms and dementia: a community-based prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

The neuropsychology of preclinical Alzheimer's disease and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Aminopyridazines inhibit beta-amyloid-induced glial activation and neuronal damage in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Aminopyridazines attenuate hippocampus-dependent behavioral deficits induced by human beta-amyloid in a murine model of neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

PET visualization of microglia in multiple sclerosis patients using [11C]PK11195

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Unchanged levels of interleukins, neopterin, interferon-gamma and tumor necrosis factor-alpha in cerebrospinal fluid of patients with dementia of the Alzheimer type.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Inflammatory proteins in plasma and the risk of dementia: the rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Neurogenesis in the adult human hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Alzheimer patients treated with an AchE inhibitor show higher IL-4 and lower IL-1 beta levels and expression in peripheral blood mononuclear cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Soluble interleukin-1 receptor type II levels are elevated in cerebrospinal fluid in Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Non-steroidal anti-inflammatory drugs (NSAIDs) in Alzheimer's disease: old and new mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Neurofibrillary tangles, amyloid, and memory in aging and mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Disruption of neurogenesis by amyloid beta-peptide, and perturbed neural progenitor cell homeostasis, in models of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Alzheimer Disease in the US Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

IL-2 and IL-6 secretion in dementia: correlation with type and severity of disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Increased hippocampal neurogenesis in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Microglia: a sensor for pathological events in the CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Inhibition by naloxone stereoisomers of beta-amyloid peptide (1-42)-induced superoxide production in microglia and degeneration of cortical and mesencephalic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Characterization of cytokine production, screening of lymphocyte subset patterns and in vitro apoptosis in healthy and Alzheimer's Disease (AD) individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Double placebo design in a prevention trial for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Polymorphisms in inflammatory genes and the risk of Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Local neuroinflammation and the progression of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Inflammatory Blockade Restores Adult Hippocampal Neurogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Glia and their cytokines in progression of neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

VLA-4/CD49d downregulated on primed T lymphocytes during interferon-beta therapy in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Inflammation and Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Current concepts in mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Neuroimaging and early diagnosis of Alzheimer disease: a look to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

The cognitive benefits of galantamine are sustained for at least 36 months: a long-term extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Treatment with an acetylcholinesterase inhibitor in Alzheimer patients modulates the expression and production of the pro-inflammatory and anti-inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Memantine in moderate-to-severe Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Clinical trial of indomethacin in Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Microglial chemotaxis, activation, and phagocytosis of amyloid beta-peptide as linked phenomena in Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Intra vitam lumbar and post mortem ventricular cerebrospinal fluid immunoreactive interleukin-6 in Alzheimer's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Peripheral cytokine release in Alzheimer patients: correlation with disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Treatment of Alzheimer's disease: current status and new perspectives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Deciphering the genesis and fate of amyloid beta-protein yields novel therapies for Alzheimer disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Neuritic plaque evolution in Alzheimer's disease is accompanied by transition of activated microglia from primed to enlarged to phagocytic forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Neurogenesis in the adult is involved in the formation of trace memories

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Central beta-amyloid peptide-induced peripheral interleukin-6 responses in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Economic impact of Alzheimer's disease in the United Kingdom. Cost of care and disease severity for non-institutionalised patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Tumor necrosis factor alters synaptic transmission in rat hippocampal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

New frontiers in Alzheimer's disease genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Intracerebral production of tumor necrosis factor-alpha, a local neuroprotective agent, in Alzheimer disease and vascular dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Intrathecal inflammation precedes development of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Early induction of interleukin-6 mRNA in the hippocampus and cortex of APPsw transgenic mice Tg2576.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

The cholinergic hypothesis of age and Alzheimer's disease-related cognitive deficits: recent challenges and their implications for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Microglial imaging with positron emission tomography and atrophy measurements with magnetic resonance imaging in multiple sclerosis: a correlative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Emerging prospects for the disease-modifying treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Discovery of a new class of synthetic protein kinase inhibitors that suppress selective aspects of glial activation and protect against beta-amyloid induced injury: a foundation for future medicinal chemistry efforts focused on targeting Alzheimer's

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Interleukin-6 and risk of cognitive decline: MacArthur studies of successful aging

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Passive amyloid immunotherapy clears amyloid and transiently activates microglia in a transgenic mouse model of amyloid deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Long-term treatment of Alzheimer disease: efficacy and safety of acetylcholinesterase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Therapeutic strategies for Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

Inflammatory markers and cognition in well-functioning African-American and white elders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

NSAIDs and incident Alzheimer’s disease. the Rotterdam study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080/02646830500382037

10.1080/02646830500382037

21 January 2018

Identifiers

DOI

1 reference

13 August 2017

1 reference